To buy or not to buy Abbott Labs? In this video, Fool health care analyst Brenton Flynn gives three reasons why you should. First, health care spending is likely to grow both in the U.S. and in emerging markets. Second, Abbott's nutrition division offers not only baby formula that is increasingly popular in emerging markets, but also diet supplements for older adults, a growing market domestically. Lastly, Abbott should increase its earnings by streamlining its operations and improving business efficiency.
Wondering about that new position in your portfolio? For some Abbott Labs shareholders, the new year brought with it a new company called AbbVie. Formerly Abbott's branded pharmaceuticals business, shares of the new stock were distributed to investors on Jan. 2. To help investors better understand the situation, The Fool has created a brand new premium report on both stocks. Inside, we outline all of the must-know opportunities and risks facing both companies, so make sure to claim this report by clicking here now.
Copyright © 2009 The Motley Fool, LLC. All rights reserved.